Is Coral Labs. overvalued or undervalued?

As of 17 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 10.25, an EV to EBIT of 5.62, and a Price to Book Value of 0.85, which all suggest a favorable valuation relative to its peers.
In comparison to its industry peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma (36.69) and Divi's Lab (69.78), both classified as expensive. Additionally, Coral Labs' EV to EBITDA of 4.95 is also more attractive than the industry average, reinforcing its undervalued status. Despite a challenging year with a stock return of -40.17%, the company's valuation metrics indicate potential for recovery and growth compared to the Sensex.